ImmuCell Corporation (ICCC) vs VAXART, INC. (VXRT)

ImmuCell Corporation and VAXART, INC. are both Biotechnology companies. ImmuCell Corporation and VAXART, INC. are of similar size ($92.4M and $90.6M). VAXART, INC. trades at the lower P/E: 2.8× against 117×. VAXART, INC. grew revenue faster over the last twelve months: 201.1% against 8.49%. VAXART, INC. has the higher net margin (15.9% vs 2.57%) and the higher return on invested capital (134.6% vs 7.84%). Across the 21 metrics below, VAXART, INC. leads on 19 and ImmuCell Corporation on 2.

Valuation

Metric ICCC VXRT Biotechnology median
P/E 117.38 2.81 7.88
P/S 2.93 0.45 11.47
P/B 2.87 1.32 2.52
Price to free cash flow 21.27 3.26 21.16
EV/EBITDA 14.22 1.49 0.74
EV/Sales 2.92 0.28 10.73
Earnings yield 0.85% 35.56% (28.84%)
Free cash flow yield 4.70% 30.65% (23.03%)

Profitability

Metric ICCC VXRT Biotechnology median
Gross margin 40.32% 100.00% 65.16%
Operating margin 12.60% 16.30% 0.00%
Net margin 2.57% 15.88% 0.00%
Free cash flow margin 13.79% 13.74% 0.00%
Return on equity 2.57% 66.97% (57.72%)
Return on assets 1.69% 23.44% (49.22%)
Return on invested capital 7.84% 134.59% 0.00%

Growth

Metric ICCC VXRT Biotechnology median
Revenue growth (TTM) 8.49% 201.10% 5.64%
EPS growth (last fiscal year) 53.85% 121.21% —
Revenue growth, 5-year CAGR 12.50% 125.76% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ICCC VXRT Biotechnology median
Debt to equity 0.26 0.00 0.00
Current ratio 4.75 1.60 4.73
Net debt to EBITDA 1.19 (2.42) 0.96

Dividend

Metric ICCC VXRT Biotechnology median
Dividend yield — 3.63% 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ICCC VXRT Biotechnology median
Market cap 90.55m 92.41m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack